SAB-142 - (SAFEGUARD)

October 1, 2026: SAB Biotherapeutics, Inc. (NASDAQ: SABS) announced upcoming presentations at the Breakthrough T1D Clinical & Research Congress (CRC 2026), October 9-11, 2026, in Philadelphia, featuring encore Phase 1 data for SAB-142 in Stage 3 type 1 diabetes.

SAB-142: A fully human anti-thymocyte immunoglobulin (hATG) immunotherapy in development for autoimmune T1D. The company said CRC 2026 presentations will include available safety and efficacy data, mechanism-of-action information, and updates on the SAFEGUARD and PRISE-hATG studies. An oral presentation on October 10 will cover “responsive C-peptide signal” in adult T1D patients more than 100 days after diagnosis, and another will discuss induction and maintenance dosing. ePosters will cover a pharmacokinetic assay, binding specificities against T-cell surface proteins, and findings that SAB-142 can be safely redosed, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers.

Current status/upcoming catalysts: SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in the registrational Phase 2b SAFEGUARD trial. Presentation materials are scheduled for October 10, 2026, with posters available throughout the conference.